A Random Interaction Forest for Prioritizing Predictive Biomarkers by Zeng, Zhen et al.
A Random Interaction Forest for Prioritizing Predictive Biomarkers 
Zhen Zeng1*, Yuefeng Lu2, Judong Shen1, Wei Zheng2, Peter Shaw1, Mary Beth Dorr1 
1 MRL, Merck & Co., Inc., Kenilworth, NJ, USA 
2 Sanofi-Aventis US LLC 
*Corresponding Author: Zhen Zeng (email: zhz43@pitt.edu) 
 
 
 
 
Abstract 
Precision medicine is becoming a focus in medical research recently, as its implementation brings values 
to all stakeholders in the healthcare system. Various statistical methodologies have been developed 
tackling problems in different aspects of this field, e.g., assessing treatment heterogeneity, identifying 
patient subgroups, or building treatment decision models. However, there is a lack of new tools devoted 
to selecting and prioritizing predictive biomarkers. We propose a novel tree-based ensemble method, 
random interaction forest (RIF), to generate predictive importance scores and prioritize candidate 
biomarkers for constructing refined treatment decision models. RIF was evaluated by comparing with the 
conventional random forest and univariable regression methods and showed favorable properties under 
various simulation scenarios. We applied the proposed RIF method to a biomarker dataset from two phase 
III clinical trials of bezlotoxumab on Clostridium difficile infection recurrence and obtained biologically 
meaningful results. 
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Introduction 
Precision medicine is a medical model that uses disease subtypes, genetic markers, and other patient-
level factors to develop customized treatment with desirable benefit-risk profiles for patients. The 
notion has been widely discussed in the public and supported by the government 1. By making optimal 
treatment decision, the practice of precision medicine helps providers deliver better healthcare to 
individual patients. From the perspective of public health, targeting treatment primarily to those who 
benefit helps optimize limited medical resources. In the pharmaceutical industry, the use of predictive 
biomarkers increases the odds of success in developing new drugs. New treatments that fail on the 
primary efficacy objective in overall population may show greater efficacy in a subpopulation. Likewise, 
the occurrence of unacceptable toxicity of new agents in some patients may be linked to specific patient 
characteristics and therefore this can be avoided if a biomarker can be found to identify patients who 
are likely to experience the toxicity. In these cases, drugs that may fail in the overall population are 
given a second chance to bring value to the right patients with the help of predictive biomarker research 
in the context of precision medicine. 
Traditionally, predefined subgroup analysis serves the purpose of precision medicine. The major issue 
with conventional subgroup analysis is that the selection of the subgroup may be subjective and limited 
by prior knowledge. An alternative approach is to carry out a series of post hoc univariable regression 
analyses with biomarker-by-treatment interactions. Such an exploratory analysis is more flexible in 
terms of the inclusion of biomarkers under consideration, but it is not meant to detect complex 
interaction forms, e.g., three-way interactions or threshold effects. For both methods, multiple 
comparisons could be a serious concern when there are many predefined subgroups or exploratory 
biomarkers. 
In clinical trials, potential predictive biomarkers, or candidate biomarkers, are generally introduced 
based on clinical relevance or screening from the hypothesis-generating approaches, such as exploratory 
pharmacogenetic and pharmacogenomic studies. The number of candidate biomarkers usually ranges 
from dozens up to a few hundreds. At such a scale, it is not feasible to directly model multiple variables 
and their interactions parametrically. As a result, data-driven approaches have been extensively 
exploited. Many tree-based machine learning methods have emerged recently and achieved marked 
performance from certain aspects, including Interaction Trees 2, Virtual Twins 3, SIDES 4 and SIDEScreen 
5, QUINT 6, GUIDE 7, and causal forests 8. 
Interaction Trees (IT) is a single-tree based method, splitting by directly searching for the most 
significant interaction effect. For each possible split value of each biomarker, a linear model is fitted with 
main effects of the treatment status and the dichotomized biomarker as well as their interaction. Split of 
a parent node is chosen based on the largest t-statistic corresponding to the interaction term, so that 
the treatment effect difference between the two child nodes is maximized. IT repeats the split on nodes 
to construct a large initial tree and then prunes the tree to control for overfitting. 
Virtual Twins (VT) has two steps. Let 𝑿 denote a vector of biomarkers or covariates, 𝒀 denote clinical 
outcomes, and 𝑻 denote the treatment status, 0 or 1. In the first step, VT predicts treatment outcome 
differences 𝝉 with 𝑿, 𝑻, 𝑿 × {𝑻 = 𝟎}, 𝑿 × {𝑻 = 𝟏} using random forest. Assuming the clinical outcome 𝒀 is 
binary with status 0 and 1, the outcome probability differences under the two potential treatments for 
each patient i is 𝝉i = P(𝒀i = 𝟏|𝑻i = 𝟏, 𝑿i) − 𝑷(𝒀i = 𝟏|𝑻i = 𝟎,  𝑿i). In the second step, a single-tree model is 
fitted on the treatment outcome differences 𝝉 with 𝑿. 
Although these methods are inspiring, they lack an assessment for variable predictive importance along 
with many other predictive modeling approaches. Some other methods, e.g., SIDEScreen and GUIDE, do 
provide importance scores for variable selection. However, their scores either are not dedicated to 
predictive utility, or have not been compared against and demonstrated superiority over traditional 
approaches, such as the importance scores from random forests or the ranking based on p-values from 
univariable regressions. 
If we can reasonably trim the candidate biomarkers down to a few highly predictive ones, it will be much 
easier to build a refined predictive model with a satisfying performance. Simple and straightforward 
methods, such as CART and regression should work well in such a case. There are also many advanced 
methods to consider, such as boosting-based methods 9. Also, in view of practice, the fewer biomarkers 
involved, the more likely a treatment decision model may be adopted and promoted. Therefore, 
identification and prioritization of predictive biomarkers is a key step for achieving precision medicine. 
Other drawbacks of existing methods include the lack of extensibility to different types of biomarkers 
and clinical outcomes, e.g., categorical or continuous biomarkers, and binary, continuous, or survival 
outcomes, as well as issues associated with single-tree models, e.g., local optimum introduced by 
greediness, inability to model complex biomarker-by-treatment interactions, and overfitting. 
To overcome the aforementioned issues, we propose a novel tree-based ensemble method, RIF 
(Random Interaction Forest), which generates predictive importance scores to prioritize biomarkers and 
is robust and extensible to various data types of biomarkers and outcomes. We compared the 
performance of RIF with random forest and univariable regression under various simulation scenarios 
and also applied it to a real clinical biomarker dataset. 
 
Methods 
The basic idea of the proposed method is to first design a tree model for capturing the biomarker-by-
treatment interaction effects, and then aggregate many of such trees to form an ensemble model. 
Similar to random forest 10, each tree in RIF is built upon a bootstrap sample. Child nodes are developed 
by searching for the best split over a subset of features (i.e., biomarkers) randomly selected. 
 
Construct an individual tree in RIF 
Unlike interaction trees, which directly split on the most significant interaction (i.e., the most significant 
difference in treatment effects between the two child nodes), trees in the proposed RIF method split on 
the most significant treatment effect in any of the two child nodes (Figure 1). The steps to build an 
individual tree can be described as follows. 
1) For all potential splits, calculate the p-values for treatment effect in the two child nodes, 
respectively, denoted as 𝑷𝟏 and 𝑷𝟐, and let 𝑷𝒎𝒊𝒏 = 𝒎𝒊𝒏 {𝑷𝟏, 𝑷𝟐}. The p-value calculation 
method depends on the outcome type. 
2) Choose the split resulting in the smallest 𝑷𝒎𝒊𝒏 
3) Continue binary split recursively to construct an individual tree 
4) Determine the terminal nodes: stop further splitting a node if it will cause the number of 
patients in any treatment arm in any of the two future child nodes below a pre-specified 
minimum. 
The trees in the proposed method guarantee a large treatment effect in one child node at each split, no 
matter what happens to the other child node. However, since the splitting is recursive, all terminal 
nodes will eventually exhibit treatment effects to the maximum extent. Using p-value rather than the 
absolute treatment effect to guide split helps strike a balance between the node size and effect size. 
Compared with interaction trees, the splitting in RIF is simpler and more natural for a tree model. 
Instead of explicitly searching for the maximum interaction effect at each split, interaction effects are 
intrinsically captured while the trees grow, because splitting based on p-values allows for various 
treatment effect directions and scales. 
The trees in RIF are flexible to model any type of outcomes. It can adapt to continuous outcome by using 
two-sample t-test for calculating 𝑷𝟏 and 𝑷2, binary outcome by using chi-square test or exact test, and 
survival outcome by using log rank test. 
To handle all types of biomarkers and reduce the search space for computational efficiency, we first 
recode categorical biomarkers to ordinal ones according to their marginal treatment effect estimate 
within each category. In the case that some categories are absent in one treatment arm but present in 
the other arm and therefore their marginal treatment effects are non-estimable, the median value is 
assigned to these categories after recoding to minimize their impact on the tree construction. In this 
way, all biomarkers are recoded to discrete quantiles (the default maximum number of quantiles is set 
to be 32). 
 
Prediction of treatment outcomes for new patients 
To predict treatment outcomes for a new patient, we first gather the biomarkers and covariates vector 
𝑿 of the new patient. Base on 𝑿 and the RIF model trained on the training data, corresponding terminal 
nodes in all trees can be located. Outcome can be predicted by taking the average outcome values of 
subjects in the corresponding terminal nodes over all trees for each treatment. Treatment effect is 
predicted by taking the difference of the predicted outcomes between two treatments. Prediction 
intervals can be generated using the collected predictions from all trees. 
 
Importance Score 
The following steps are used to compute variable predictive importance scores: 
1) Run RIF to get the prediction model 𝑴 
2) Make predictions of treatment effect 𝑴(𝑫) for all the training data 𝑫 
3) Assume the total number of biomarkers is 𝒑, generate a series of disrupted data 𝑫′𝟏, …, 𝑫′𝒑 by 
substituting each feature in the training data with its mean, respectively 
4) Make predictions of treatment effect for the disrupted data 𝑴(𝑫′𝟏), …, 𝑴(𝑫′𝒑) 
5) Define the importance score 𝑰𝑺 as the squared Euclidean distance between the two sets of 
predicted treatment effects for all subjects over all trees 
    𝑰𝑺𝒊 = ||𝑴(𝑫) − 𝑴(𝑫′𝒊)||𝟐 𝟐 
              𝒊 = 𝟏, …, 𝒑 
Note that larger important scores indicate higher predictive ability. 
 
Simulation 
Setup 
The performance of RIF on predictive biomarker prioritization was evaluated under four different 
scenarios by simulation (Table 1). Two treatment arms were considered. In each scenario, 60 candidate 
biomarkers were simulated, of which 30 are continuous with standard normal distribution and 30 are 
categorical with 4 levels evenly distributed. Among the 60 candidates, two continuous ones were truly 
predictive: X1 with both predictive and prognostic effects, and X2 with pure predictive effect. Besides, 
four biomarkers, X3 to X6, had prognostic effects with various magnitudes. Continuous treatment 
outcomes were considered in scenarios 1 and 2, with normally distributed residual errors ε ~ N (0, 1), 
and binary treatment outcomes were considered in scenarios 3 and 4. In scenario 1 and 3, a linear 
additive predictive effect was imposed between X1 and X2. In scenario 2 and 4, a joint threshold 
predictive effect was present between X1 and X2 (i.e., a three-way interaction among X1, X2, and 𝑻). 
More details of the underlying true models can be found in Table 1. 
Denote the total sample size as 𝑵. For each scenario, three different sample sizes were tested: a small 
sample size of 𝑵=200 (100 in each treatment arm); a medium sample size of 𝑵=400 (200 in each 
treatment arm), and a large sample size of 𝑵=1000 (500 in each treatment arm). 500 simulations were 
run for each combination of the four scenarios and three sample sizes. 
The parameters for random interaction forests were set as: 500 trees in each RIF; 𝒑/𝟑 candidate 
biomarkers randomly selected for each split; and 𝑵/100 minimum number of patients in any treatment 
arm to determine the terminal nodes. 
The proposed method RIF was evaluated by comparing with the two conventional univariable regression 
and random forest methods. A series of linear regression (for continuous outcomes) or logistic 
regression (for binary outcomes) were conducted for each biomarker, with treatment and biomarker 
main effects and their interaction in the model. The p-value from a 2-degrees-of-freedom joint test for 
the biomarker main effect and interaction was used to rank the predictive importance. We denote this 
approach as UnivarLR. Random forests with default settings 13 were performed on each treatment arm 
separately to generate two sets of variable importance scores. Biomarkers were ranked based on the 
better ranking between the two sets. This approach was denoted as RF. Alternatively, random forest 
was performed on the predicted treatment effects from the first step of VT (see introduction), and the 
variable importance scores were used for ranking, denoted as RF2. 
 
Results 
Figure 2 shows the results of simulation. The curves are analogs to the receiver operating characteristic 
curve, with y axis being the probability of identifying true predictive variables and x axis being the 
average number of non-predictive variables included, illustrating the successful rate against the amount 
of noise allowed across all simulation repeats. The curves were generated based on an increasing 
number of prioritized variables, starting from one. A curve above the other one indicates the 
corresponding method outperforms the other method. 
No single method dominates all competitors for all scenarios. However, it is noticeable that RIF 
outperforms all the others in scenario 4, where the outcome is binary and the two predictive biomarkers 
form a joint threshold effect naturally defining a subgroup. With a moderately large sample size 
(𝑵=1000), RIF achieved an approximate gain of 0.1 in the probability of identifying the truth compared 
with the second best, RF2. The performance of RIF and RF2 were similar in scenario 3, where the 
outcome is binary and the predictive effects are linear additive. For scenarios 1 and 2, our method 
outperformed RF2 if very few (≤ 3 in most cases) top-ranking biomarkers are in the prioritization list. 
When more biomarkers are allowed in, RF2 achieved a better detection power. 
In general, the performance of UnivarLR and RF were worse than RIF and RF2, and appeared to be 
better than each other when the true predictive effect was linear additive or a joint threshold, since the 
former fits the assumption of UnivarLR and the latter is easy to be detected by tree models. It is 
noteworthy that both of these methods target pure prognostic effects, too. On the contrary, RIF and RF2 
are robust to the presence of prognostic effects. 
 
Real Biomarker Data Analysis 
We illustrated our methods on a real biomarker dataset from two phase 3 clinical trials, MODIFY I and 
MODIFY II 11, investigating the effect of human monoclonal antibodies against Clostridium difficile (C. 
diff) toxins on the recurrence of C. diff infection (CDI). The primary end point was CDI recurrence, 
defined as the binary status of the presence of new CDI episode after initial clinical cure, within 12 
weeks after infusion of the study medication. We were interested in identifying patient-level variables 
that influence the efficacy of treatment with bezlotoxumab (human monoclonal antibody against C. diff 
toxin B) versus treatment without bezlotoxumab. A total of 782 eligible subjects who achieved initial 
clinical cure were included in the analysis. Among the 38 variables considered (𝑿), 20 were categorical 
and 18 were continuous, including patient demographic data, disease status and history, baseline 
laboratory assessments, host genetic variants and background, pathogen strain type and lineage at 
baseline, and randomization stratification factors (see supplemental materials for variable annotation). 
Of note, after excluding redundant significant signals, two host single nucleotide polymorphisms (SNPs) 
and one human leukocyte antigen (HLA) allele, coded numerically as 0, 1, and 2 (number of allele of 
interest), as well as five principal components characterizing patient genetic background, from previous 
pharmacogenetic genome-wide association studies 12, were included in the variable set. 
Missing values in 𝑿 were imputed using the “rfImpute” function from R package “randomForest” 13. The 
results of RIF were compared with the aforementioned methods in the simulation section. We grew 
1000 trees in RF, RF2, and RIF. To determine if a biomarker is significantly predictive with UnivarLR, a p-
value threshold of 0.0013 was adopted based on Bonferroni correction. For other methods, significance 
of predictive biomarkers was determined by repeatedly applying Grubbs’ test for one outlier 14 on the 
importance scores. If the variable with the largest important score is significant (p-value < 0.05), it was 
removed and the same procedure was applied to the rest until all significant variables were identified. 
The top 8 most predictive variables prioritized by each method were presented in Table 2. RIF identified 
two significant variables, a host SNP rs76166871 and REA group. The other host SNP rs2516513 and HLA 
allele DRB1*07:01 were not significant by Grubbs’ test, but were ranked among the top 4. Although the 
analysis was totally data-driven, these results convey biology explanation and clinical relevance. Note 
that both SNPs are located on chromosome 6p, where the HLA region is harbored. Along with the HLA 
allele DRB1*07:01, these host genetic variants may impact the modulation or regulation of immune 
response to CDI. On the other hand, restriction endonuclease analysis (REA) is a classification of 
pathogen strain type based on C. diff genetic diversity. REA grouping is informative on the toxin 
classification of the isolates, including toxin variant types. Therefore, RIF identified and prioritized host 
and pathogen genetic factors as the most predictive variables. These findings supported the 
involvement of host and pathogen genetic factors, as well as a possible interplay, in the mechanism of 
action of bezlotoxumab. 
Other variables in the top lists worth mentioning were principal components (PC1 to PC5, relevant to 
patient genetic background), country name (CNTRYNAM, a confounder to both principal components 
and pathogen diversity), age (AGE, a known prognostic variable), status of prior history of CDI in the past 
6 months (HX6M), status of any prior history of CDI (CDIEVER), and number of CDI episodes in the past 6 
months (EP6MN). 
It was not surprising that UnivarLR identified all three host genetics variants as significant, as they were 
from previous pharmacogenetics screening using the same analysis approach. UnivarLR also identified 
the most variables. This may be due to an inadequate power of Grubbs’ test when the number of 
candidate variables is relatively small or when many truly predictive ones exist. Therefore, Grubbs’ test 
should be used with caution. Instead, an arbitrary cut-off may be more practical to select variables in 
that the bottleneck is the feasibility of building a final treatment decision model. 
 Discussion 
Our method enjoyed several favorable properties compared with RF2. First, RIF was more sensitive 
under stringent variable selection. In other words, if our focus is the top few variables (≤ 3 in our 
simulation cases) in the prioritization list, RIF is more likely to pick up the truth than other methods. This 
is of important practical value, since it is essential to keep treatment decision models as simple and 
sparse as possible so that they can be easily tested and implemented in reality. Any decision model 
requiring more than three biomarkers is almost prohibitive in practice. Secondly, RIF showed a 
considerable improvement for scenario 4 when the sample size is moderately large, which is a common 
and reasonable case in reality. Actually, our real data analysis example is one of such cases. However, 
there is still a lack of theoretical explanation for these simulation findings. Future endeavors on the 
theoretical analysis to back these properties up are warranted. Thirdly, RF2 may be biased toward 
categorical variables with many levels, because many dummy variables and interaction terms have to be 
introduced for handling them, while RIF is not affected by this issue. 
Sometimes, it is desirable to adjust for nuisance covariates. For example, there are cases where 
variables known to impact the outcomes are not considered as candidates for predictive effect. One way 
to handle this is to first regress out the effects of these variables, and then applying RIF on the outcome 
residuals. However, this only works for continuous outcomes. For binary or survival outcomes, as a 
future work, we may consider using a regression model to adjust for nuisance covariates when splitting 
nodes. The other way is to include nuisance covariates as variables in RIF, but simply ignore them when 
interpreting the results and selecting predictive variables. In our real data analysis, randomization 
stratification factors (the standard-of-care and hospitalization status) and principal components were 
such nuisance variables. The need to adjust for nuisance covariates is more common when dealing with 
data from observational studies. 
Although our method was proposed in the context of biomarker prioritization for the use in precision 
medicine, it is applicable to any predictive variables analysis and problem of interaction detection. In the 
present work, we only investigated RIF’s performance on predictive variable prioritization. It is 
warranted to explore its performance on other uses and possible extensions, such as for individual 
treatment effect prediction, on survival outcomes, on multivariate outcomes, as well as on longitudinal 
data. 
To summarize, our methods provide a powerful tool, RIF, for prioritizing predictive biomarkers. RIF is 
implemented in R. The code is available for research purposes upon request. 
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Figure 1. Define the best split of a node to construct trees in RIF. 
 
  
a. Scenario 1 
 b. Scenario 2 
 
 c. Scenario 3 
 
 d. Scenario 4 
Figure 2. Simulation results of the four scenarios. Each panel represents one scenario. The results of 
different sample sizes are displayed by column within each panel. Four different methods are indicated 
by line type. The curves show the probabilities of identifying the true predictive variables (y-axis): X1 (top 
row in each panel), X2 (middle row in each panel), and both (bottom row in each panel), against the 
average number of non-predictive variables included (x-axis), with the number of variables in the 
prioritization list increasing. 
 Table 1. True models of the four simulation scenarios. Two predictive variables X1 and X2 are highlighted 
in bold. The visualization of each scenario displays the varying treatment effect as the values of X1 (in x-
axis) and X2 (in y-axis) increase. Red, black, and green colors indicate high, medium, and low values of 
treatment effect, respectively. 
 
Scenario True Model Visualization 
Continuous  
Outcomes 
Scenario 1 
𝒀 = 𝟏 + 0.25𝑻 + (-0.4𝑿𝟏 + 0.2𝑿𝟐)𝑻 + 0.2𝑿𝟏 + 0.1𝑿3 + 
0.1𝑿4 + 0.2𝑿5 + 0.5𝑿6 + 𝜀 
 
Scenario 2 
𝒀 = 𝟏 + 0.25𝑻 + 𝑰{𝑿𝟏 < 𝟎.𝟐, 𝑿𝟐 < 𝟎.𝟐}𝑻 + 0.1𝑿𝟏 + 0.1𝑿3 
+ 0.2𝑿4 + 0.2𝑿5 + 0.5𝑿6 + 𝜀 
 
Binary 
Outcomes 
Scenario 3 
Logit(E[𝒀]) = 𝟏 + 0.25𝑻 + (-0.4𝑿𝟏 + 0.2𝑿𝟐)𝑻 + 0.2𝑿𝟏 + 
0.1𝑿3 + 0.1𝑿4 + 0.2𝑿5 + 0.5𝑿6 
 
Scenario 4 
Logit(E[𝒀]) = 𝟏 + 0.25𝑻 + 𝑰{𝑿𝟏 < 𝟎.𝟐, 𝑿𝟐 < 𝟎.𝟐}𝑻 + 
0.1𝑿𝟏 + 0.1𝑿3 + 0.2𝑿4 + 0.2𝑿5 + 0.5𝑿6 
 
 
 
 
 
 
Table 2. Top 8 most predictive variables ranked by different methods (see supplemental materials for 
full results). 
Method Rank 1 2 3 4 5 6 7 8 
UnivarLR 
Variable rs76166871 rs2516513 DRB1*07:01 HX6M CDIEVER EP6MN HEPATIC HYPVGRP 
P-value 3.4E-08 2.0E-07 1.6E-05 3.8E-05 1.2E-04 5.4E-04 2.2E-03 5.1E-03 
Grubbs’ test NAb NA NA NA NA NA NA NA 
RF 
T = 0 
Variable REA CNTRYNAM PC1 AGE WEIGHT PC3 PC2 PC5 
ISa 11.15 10.63 9.16 8.73 8.34 7.89 7.71 7.46 
Grubbs’ test NSc NS NS NS NS NS NS NS 
T = 1 
Variable CNTRYNAM PC4 REA ALB_VAL PC5 WEIGHT PC2 PC1 
IS 13.81 10.57 10.35 9.80 9.68 8.96 8.88 8.53 
Grubbs’ test NS NS NS NS NS NS NS NS 
RF2 
Variable CNTRYNAM REA rs76166871 AGE PC4 WEIGHT ALB_VAL rs2516513 
IS 6.24 5.19 3.74 3.54 3.37 3.21 3.13 3.13 
Grubbs’ test 0.026 NS NS NS NS NS NS NS 
RIF 
Variable rs76166871 REA rs2516513 DRB1*07:01 PC4 PC2 AGE CNTRYNAM 
IS 0.256 0.081 0.061 0.047 0.047 0.046 0.042 0.037 
Grubbs’ test 8.9E-13 0.015 NS NS NS NS NS NS 
a. IS: important score; b. NA: not available; c. NS: not significant. Significant predictive variables were 
highlighted in bold. 
 
